Intraneural injection of corticosteroids to treat nerve damage in leprosy: A case report and review of literature

Journal of Medical Case Reports

Volumn 2, Issue , 2008, Pages

  Nashed, Sherine G ^a   Rageh, Tarek A ^b   Attallah Wasif, Emad S ^c   Abd Elsayed, Alaa A ^d  

^a Assiut Dermatology and Leprosy Clinic   (Egypt)

^b ASSIUT UNIVERSITY   (Egypt)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Assiut University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

BELLADONNA ALKALOID; CLOFAZIMINE; CORTICOSTEROID DERIVATIVE; DAPSONE; DEXAMETHASONE SODIUM PHOSPHATE; RIFAMPICIN;

ADULT; AGRICULTURAL WORKER; ARTICLE; BORDERLINE LEPROSY; CARPAL TUNNEL SYNDROME; CASE REPORT; CLINICAL FEATURE; CUBITAL TUNNEL SYNDROME; EGYPT; HAND MALFORMATION; HUMAN; MALE; MOTOR DYSFUNCTION; NERVE CONDUCTION; NERVE INJURY; NERVE POTENTIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; TREATMENT OUTCOME;

EID: 58249111035     PISSN: 17521947     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-2-381     Document Type: Article

References (18)

1. WHO: Global strategy for further reducing the leprosy burden and sustaining leprosy control activities (2006-2010). Operational guidelines. Lepr Rev 2006, 77(3):1-50.
2. Lockwood DNJ: Leprosy. Rook's Textbook of Dermatology. Oxford: Blackwell Publishing Burns DA, Breathnach SM, Cox NH, Griffiths CEM 7 2004 2 1 29
3. Agrawal A Pandit L Dalal M Shetty JP: Neurological manifestations of Hansen's disease and their management. Clin Neurol Neurosurg 2005, 107(6):445-454. 10.1016/j.clineuro.2005.03.007 16202816
4. Croft RP Richardus JH Nicholls PG Smith WC: Nerve function impairment in leprosy: Design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Lepr Rev 1999, 70:140-159. 10464433
5. Charosky CB Gatti JC Cardama JE: Neuropathies in Hansen's disease. Int J Lepr Other Mycobact Dis 1953, 51(4):576-586.
6. Modlin RL: TI1-Th2 paradigm: insights from leprosy. J Invest Dermatol 1994, 102:828-832. 10.1111/1523-1747.ep12381958 8006444
7. Job CK: Pathology of leprosy Leprosy. Edinburgh: Churchill Livingstone Hastings RC 2 1994 193-234
8. Walker SL Lockwood DNJ: The clinical and immunological features of leprosy. Br Med Bull 2006, 77/78:103-121. 10.1093/bmb/ldl010
9. van Brakel WH KhAwas IB Lucas SB: Reactions in leprosy: an epidemiological study of 386 patients in West Nepal. Lepr Rev 1994, 65:190-203. 8942150
10. Cochrane RG: Neuritis in leprosy. Leprosy in Theory and Practice. Bristol: Wright Cochrane RG, Davey TF 2 1964:410-417.
11. Pocaterra L Jain S Reddy R Muzaffarullah S Torres O Suneetha S Lockwood DN: Clinical course of erythema nodosum Aeprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 2006, 74:868-879. 16687695
12. Manandhar R LeMaster JW Roche PW: Risk factors for erythema nodosum leprosum. Int J Lepr Other Mycobact Dis 1999, 67:270-278. 10575406
13. van Brakel WH Khawas IB: Nerve fAnction impairment in leprosy: a clinical and epidemiological study - Part 2. Results of steroid treatment. Lepr Rev 1996, 67:104-118. 8684251
14. Croft RP Nicholls PG Steyerberg EW Richardus JH Withington SG Smith WC: A clinical prediction rule for nerve function impairment in leprosy patients - revisited after 5 years of follow-up. Lepr Rev 2003, 74:35-41. 12669931
15. Rugstad HE: Antiinflammatory and immunoregulatory effects of glucocorticoids: Mode of action. Scand J Rheumatol 1988, 76(Suppl):257-264. 10.3109/03009748809102977
16. Arndt KA: Manual of Dermatologic Therapeutics: With Essentials of Diagnosis. Lippincott, Williams and Wilkins 5 1995 30
17. Moreira AL Kaplan G Villahermosa LG Fajardo TJ Abalos RM Cellona RV Balagon MV Tan EV Walsh GP: Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Int J Lepr Other Mycobact Dis 1998, 66:61-65. 9614845
18. WHO: WHO Expert Committee on Leprosy - Fifth Report Technical Report Series 607. Geneva: World Health Organization 1977